Wesbanco Bank Inc. Has $2.75 Million Stake in Danaher Co. (NYSE:DHR)

Wesbanco Bank Inc. cut its stake in Danaher Co. (NYSE:DHR) by 0.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,992 shares of the conglomerate’s stock after selling 67 shares during the quarter. Wesbanco Bank Inc.’s holdings in Danaher were worth $2,753,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of DHR. Decker Retirement Planning Inc. bought a new stake in Danaher in the fourth quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new position in shares of Danaher in the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the 3rd quarter valued at $40,000. FSA Wealth Management LLC acquired a new stake in Danaher during the 3rd quarter worth $50,000. Finally, Darwin Wealth Management LLC bought a new position in Danaher during the third quarter worth about $55,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of DHR opened at $245.73 on Friday. The company’s fifty day simple moving average is $234.90 and its 200 day simple moving average is $253.47. Danaher Co. has a 1-year low of $225.42 and a 1-year high of $281.70. The company has a market cap of $177.49 billion, a price-to-earnings ratio of 46.90, a PEG ratio of 4.43 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. Danaher’s revenue was up 3.1% on a year-over-year basis. During the same period last year, the business posted $2.02 EPS. On average, research analysts forecast that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio is currently 20.61%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Scotiabank initiated coverage on Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target on the stock. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target on the stock in a research note on Friday, December 13th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Guggenheim assumed coverage on shares of Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price objective on the stock. Finally, TD Cowen increased their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $285.55.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.